New Tools for the Enhanced
|
|
- Bryce Tate
- 6 years ago
- Views:
Transcription
1 New Tools for the Enhanced Management of Chronic Disease Based on a Proprietary, Point of Care, Electrochemical Detection System Universal Biosensors Investor Presentation February
2 Important disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. This presentation is not financial advice and has been prepared without taking into account the objectives, financial situation or needs of a particular person. Neither the Company, nor its officers or advisors or any other person warrants the accuracy of the analysis herein or guarantees the investment performance of the Company. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Under applicable United States securities laws all of the shares of our common stock are restricted securities as that term is defined in Rule 144 under the Securities Act of 1933, as amended (Securities Act). Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders. The statements contained in this presentation that are not purely historical are forwardlooking statements within the meaning of the Exchange Act. Forward-looking statements in this presentation include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this presentation are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. The Company is subject to anumber of risks. For a summary of key risks, refer to the Company s most recent Form 10-K filed with the United States Securities and Exchange Commission. 2
3 Creating Shareholder Value 1 Creating a sustainable operating Our unique platform is validated Product developed for the biggest market Partnered with a market leader 2 of growth opportunities of new in development Replicate commercialisation strategy Strong IP suite Capitalising on market : 3 Capitalising on emerging imperatives Companion diagnostics Evidence based medicine Personalised medicine 3 3
4 Timeliness - A Key Missing Link Diagnosis and monitoring relies largely on central lab testing Automation has driven costs down in these settings Logistics and time are major drawbacks for this structure Improved and timely clinical decisions possible with robust Point Of Care Tests 44
5 The In Vitro Diagnostics Market busiess Central lab 5% CAGR The Global IVD market IVD market segments (2005) 2008 market size ~US$40bn Other 17% Glucose monitoring 21% Microbiology 1% Point of Care Molecular 10 12% CAGR 7% 36% Other POC Hemostasis 64% 15% 9% Immunoassays 16% Clinical chemistry 14% The glucose monitoring market is the biggest and most mature segment of the IVD Point of Care (POC) industry The total POC market expected to approach ~US$18bn by 2012 growing at 10-12% 12% pa. Second largest IVD segment is immunoassay where we are developing a new capability. Molecular Dx is the fastest growing IVD segment (>15% CAGR). 5
6 Initial Product Blood Glucose Test Used as part of the treatment of diabetes The market is large, established and still growing g Our product has market leading attributes and our partnership with a market leader, LifeScan, means that we have a powerful offering This is targeted to provide a stable and sustainable income base to Universal Biosensors. Total value will be determined by the commercial success of the Partnership with LifeScan, a part of J&J 6 6
7 The Most Accurate No-coding Blood Glucose Monitoring System Available LifeScan s One Touch Verio launched in The Netherlands Jan $US16 million milestone payment received in Nov First SMGB system labeled to meet specifications tighter than current ISO specification Targeted at Type 1 and Type 2 diabetic insulin users 7
8 UBI and LifeScan (blood glucose/diabetes) A Strong Relationship Licence Agreement Development and Research Agreement Johnson and Johnson Development Corporation equity investment Master Services and Supply Agreement (MSSA) Fee for Service (scale up tasks) Manufacturing Process Support Agreement (2008) MSSA updated Development and Research Agreement updated LifeScan launch of first UBI developed product 88
9 UBI - LifeScan The Master Services and Supply Agreement: - Is an umbrella agreement permitting multiple and services - UBI is a (non-exclusive) manufacturer of sensor strips - UBI will develop other for LifeScan Provides UBI revenue from: - Milestone payments for R&D success - Providing R&D services to LifeScan - Manufacturing blood glucose strips - Service fee based on strips sold 99
10 The Glucose Operating Business Steady ramp up in markets expected over next few years LifeScan continuing with increased level of research and development funding to UBI to improve existing technologies UBI GMP strip manufacturing plant in Rowville (Melbourne), Australia is the current sole manufacturer of strips for the new product - Installed capacity for 750 million strips pa - Second line in progress We expect LifeScan to commission initial capacity of its own in
11 Glucose Market Information From Published Sources: - Roche Diabetes Care sales grew 6% in Bayer Diabetes sales grew 6.8% (FX adjusted) in qtr with Contour product growing 15% - J&J Diabetes sales reduced by 1.3% (FX adjusted) in Overall market thought to be flat in 2009 due to Global Financial Crises ( Roche Annual Report)» Source Annual Reports of Roche and J&J and Quarter Report for Bayer 11
12 Flexible Platform Creates Many Opportunities Glucose test 1 Future development hscrp 2 D-dimer 4 3 PT test 12
13 Dry Immunoassay Meter Body With soft edges for better grip, maneuverability and comfort Unique Shape Differentiates product and allows for right and lefthanded use Touch Screen With dark background to minimise power use. Visual and audible feedback Mechanical integral on/ off switch Integral to front face for ingress protection Barcode Scanner Runway For easier strip insertion Strip Ejection Mechanism Stable on flat surface 13
14 Advantages of UBI Platform Easy to use Derived from a product successfully used over 16bn times a year (blood glucose strip) - Minimal user steps - Small finger stick sample Quantitative Accurate and Precise - Competitive with lab based tests Timely Results produced quickly - Tests expected to produce results in a matter of minutes Low cost Simple design and automated manufacturing process dramatically reduces costs - UBI can be the low cost producer Flexible Platform can be adapted to develop tools for many other biomarkers Attractive as: - Part of companion diagnostics for Pharma - Timely intervention in a diagnostic setting 14
15 Product APPLY CORE TECHNOLOGY: OPPOSED ELECTRODES, ALGORITHM, WEB BASED MANUFACTURE PROTO- TYPE DEVELOP- MENT CYCLE PRODUCTION CAPABILITY/ CAPACITY MARKET REACH MARKET LAUNCH MARKET EXPANSION Enhanced Blood Glucose Product Launched Immunoassay platform - CRP Built, awaiting installation Active Business Development efforts underway 2011 Enzyme activity platform - Prothrombin Time Development hold until partnered Uses immunoassay line Active Business Development efforts for commercial partner underway Immunoassay platform -D- Dimer Development slowed until partnered Uses immunoassay line Active Business Development efforts underway Nucleic acid platform 15
16 Technology Opposing electrodes which are close to one another are used to improve the electrochemical measurement of reactions in the blood. New approach allowed broad patent suite The novel electrochemical cell in the test strip is designed to allow for greater accuracy, without t sacrificing i speed 16
17 Protected - Extensive Licensed and Owned IP 42 patent families covering, manufacturing, core and peripheral technology 245 granted patents 259 pending applications 504 patents plus applications 17
18 Current Healthcare Trends are Financially Unsustainable Budget balance 2009E (% GDP) % GDP on healthcare Healthcare spending per capita Growth in healthcare exp. per capita (pa.) ( ) US (13.5%) 16.0% US$7, % France (8.2%) 11.0% US$3, % Germany (4.6%) 10.4% US$3, % Italy (5.3%) 8.7% US$2, % Australia (3.8%) 8.7% US$3, % UK (14.4%) 8.4% US$2, % Japan (7.4%) 8.1% US$2, % Sources: OECD, The Economist 18 18
19 Current Healthcare Trends are Financially Unsustainable Aging population Increased incidence of chronic disease Additional ~500m people expected to be aged over 60 in next 20 years - Increase in demand for healthcare - Reduction in Medicare contributions +80% of people over 60 in the US have at least one chronic disease 50% have at least 2 Chronic diseases and 20% have diabetes Major chronic diseases include: - Diabetes, Cardiovascular disease, COPD, Cancer, Arthritis Technology gap Major GP tools have not changed since the 1970 s Most drugs only work in % of patients SOMETHING HAS TO CHANGE! 19
20 Industry Views By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals id to take charge of improving i their health and quality of life. A global leader in rapid point-ofcare diagnostics, Inverness, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women s health. Focus on areas for which near patient diagnosis and monitoring i can profoundly change therapy decisions, i improve outcomes and lower costs. Inverness Medical Presentation to UBS Healthcare Conference
21 Complex Made Simple with the Power of the Technology 50 Correct for antioxidants Current (microamps) Distinguish blood from control solution Monitor the reaction kinetics Measure concentration or reacted species Time (s) Powerful algorithms Powerful breadth Powerful manufacturing Whole blood finger stick sample Accurate for the individual Comprehensive Care Robust, Reliable, Affordable Helps better meet the needs of patients 21
22 Capital structure Summary Number of Shares on issue 157,233,266 Market capitalization at 16 Feb 2010 ~A$275 million Number of Options on issue 10,024,153 Cash (at 31 Dec 2009) ~A$31.3 million 22
Siemens showcases prothrombin time testing system developed with Universal Biosensors at IFCC EuromedLab 2013 in Milan, Italy
Universal Biosensors Inc ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email info@universalbiosensors.com www.universalbiosensors.com
More informationGlobal In-Vitro Diagnostic Market Report
Global In-Vitro Diagnostic Market Report ----------------------------------------------------- 2013 Executive Summary The process of performing a diagnostic test outside of a living organism in an artificial
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationGlobal In-Vitro Diagnostics (IVD) Market Report
Global In-Vitro Diagnostics (IVD) Market Report ----------------------------------------- 215 Executive Summary The diagnostic industry is widely classified into two types: In-vitro diagnostics and In-vivo
More informationDisclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
More informationWhat it takes to make a new state of the art diagnostics platform for Point of Care use.
What it takes to make a new state of the art diagnostics platform for Point of Care use. 31.10.2006 Axis-Shield plc 450 employees Turnover 58 million Profit before tax 1,9 million R&D spend 7,4 million
More informationCEO Presentation Annual General Meeting
ASX code: LBT lbtinnovations.com CEO Presentation Annual General Meeting Adelaide, Australia 21 October 2015 Lusia Guthrie, CEO Disclaimer This document contains certain forward-looking statements that
More informationFrom Resilience To Growth:
From Resilience To Growth: Mapping a New Direction for Life Sciences & Medical Devices Attorney Advertising Prior results do not guarantee a similar outcome Models used are not Mapping the Way: Opportunities
More informationTecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA
Tecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA Safe Habor Statement All statements in this presentation not referring to historical
More informationInvestor Presentation
Siemens Ltd., 2 www.siemens.co.in Disclaimer This presentation has been prepared solely for use at the investor/analyst presentation. By attending the meeting where this presentation is made, or by reading
More informationFor personal use only
Shareholder Presentation Perth, WA Annual General Meeting 17th November 2016 Global leader in applying proteomics to MedTech ASX: PIQ 1 Disclaimer & forward-looking statements This Presentation is provided
More informationBiocartis: pushing boundaries in healthcare. Hilde Windels Dag van de Tips 10 October 2015
Biocartis: pushing boundaries in healthcare Hilde Windels Dag van de Tips 10 October 2015 2 NOTICES AND WARNINGS This presentation has been prepared by the management of Biocartis Group NV (the "Company").
More informationAkers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers
Akers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers 1 All statements pertaining to future financial and/or operating results,
More informationPharma R&D and Patents support Health Care & Economy
Pharma R&D and Patents support Health Care & Economy Konstantinos Μ. Frouzis President of SFEE, V.P & Gen. Manager of Novartis Hellas April 28 th, 2014 Intellectual Property Patents: The vehicle for innovation
More informationAkers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers
Akers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers 1 All statements pertaining to future financial and/or operating results,
More informationAbcam Plc. JP Morgan Healthcare Conference January 2017
Abcam Plc JP Morgan Healthcare Conference January 2017 2 Disclaimer Important information The information provided in this presentation is for the sole use of those attending the presentation; it shall
More informationQIAGEN Sample & Assay Technologies From Discovery to Patient
QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this
More informationThe China In Vitro Diagnostics (IVD) Market has been analyzed from 4 View Points:
China In Vitro Diagnostics (IVD) Market - Overview China In-Vitro Diagnostics (IVD) market is among the fastest growing in the world. It is anticipated that China IVD market will more than triple by 2020
More informationRoche in Switzerland
Roche in Switzerland A leader around the world and at home Last year Roche employed some 13,000 employees from over 90 countries in Switzerland. This makes Switzerland one of Roche s three largest locations
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationGlobal Molecular Diagnostics Market Report
Global Molecular Diagnostics Market Report ----------------------------------------- 2014 Executive Summary Over the years, medical science has made unprecedented progress in almost every sphere of human
More informationMolecular Diagnostics for Global Heath Problems. Proactive Investors Forum 5 October 2017
Molecular Diagnostics for Global Heath Problems Proactive Investors Forum 5 October 2017 2 Document Information The information contained in this document and made verbally to you (together the Presentation
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationMolecular Diagnostics at the Point of Need
Molecular Diagnostics at the Point of Need 24 November 2016 David Budd CEO d.budd@genedrive.com 1 DOCUMENT INFORMATION The information contained in this document and made verbally to you (together the
More informationMoberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY
Moberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY Corporate Presentation Remium Health Care Capital Market Day Dec 2, 2013 Peter Wolpert, CEO and Founder Disclaimer Statements included herein that are
More informationThe European Medical Technology Industry. in figures / 2018
The European Medical Technology Industry in figures / 2018 Table of contents What is Medical Technology? 4 Innovation 10 Employment 14 Companies 18 Expenditure on Medical Technology 20 MedTech Market in
More informationUBS Global Life Sciences Conference
September 20, 2011 UBS Global Life Sciences Conference Tecan Group AG Dr. Rudolf Eugster, CFO September 20, 2011 / p2 / UBS GLSC Contents Introducing Tecan Strategic Growth Drivers Financials H1 2011 &
More information35th Annual J.P. Morgan Healthcare Conference
35th Annual J.P. Morgan Healthcare Conference Investor Presentation Nachum Homi Shamir President and Chief Executive Officer January, 2017 Safe Harbor Statement Certain statements made during the course
More informationDedicated to Molecular Diagnostics
Dedicated to Molecular Diagnostics For Europe Sample & Assay Technologies QIAGEN s growing role in molecular diagnostics At QIAGEN, one of our key goals is to support clinical decision-making and improve
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationJP Morgan Global Healthcare Conference
JP Morgan Global Healthcare Conference January 12, 2016 Robert Friel, Chairman and CEO Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking" statements
More informationQ Presentation , Oslo
Q4 2017 Presentation 01.02.2018, Oslo Agenda Highlights BetaGlucans Animal- and Consumer health Cancer Advanced wound care Enzymes Molecular and new markets Q4 Financials Outlook for 2018 2 Biotec in brief
More informationAlmac Overview.
Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide
More informationProteomics International Laboratories Ltd
Proteomics International Laboratories Ltd PIQ: ASX: A$0.24 Recommendation: Buy Price Target: A$0.45 retained Launch of its PromarkerD diagnostic test in February 2018 Potential strong deal flow and cash
More informationWebinar July 9, Noon. The Essentials of Diagnostics: Introduction to Molecular Diagnostics
Webinar July 9, 2013 12 Noon The Essentials of Diagnostics: Introduction to Molecular Diagnostics 1 DxInsights mission is to educate healthcare stakeholders on the power and value of diagnostics and their
More informationBuilding a Career in the Pharmaceutical Industry: Personal Reflections. Carlo Nalin, PhD Executive Director Novartis Oncology
Building a Career in the Pharmaceutical Industry: Personal Reflections Carlo Nalin, PhD Executive Director Novartis Oncology 2 Career Development: Personal Reflections C Nalin 5 April 2016 Cornell BEST
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationBank of America Merrill Lynch Healthcare Conference. September 13, 2013
Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. India In-Vitro Diagnostics Market Introduction Market Overview Growth Drivers Constraints Regulatory Framework and Accreditation 2. India In-Vitro Diagnostics Market Size by Revenues,
More informationFor personal use only
Proteomics International Laboratories Ltd Investor Presentation June 2015 Global leader & innovator in the field of proteomics ASX: PIQ 1 Disclaimer and Forward looking statements This Presentation is
More informationUBS Global Life Sciences Conference
September 21, 2010 UBS Global Life Sciences Conference Tecan Group AG Thomas Bachmann, CEO September 21, 2010 / p2 / UBS Global Life Sciences Conference Introducing Tecan Provider of instruments and workflow-solutions
More informationBiopharmaceuticals Investor & Analyst Day
Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationH&M group capital markets day Stockholm 2018 H&M GROUP CAPITAL MARKETS DAY 2018
H&M group capital markets day Stockholm 2018 Disclaimer THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES. IT IS SOLELY FOR USE AT A CAPITAL MARKETS EVENT AND IS PROVIDED
More informationFor personal use only. Medical Nutrition Investment Company
Medical Nutrition Investment Company Investment Focus Eve s vision is to be a leading Australia Investment company in the rapidly growing Global Medical Nutrition sector. Investing in businesses in the
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationEARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles
EARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles BrainDTech Team Dr. Pietro Conti, MD, MBA President Medicine & MBA Founder/CEO several startups
More informationFlexible, robust solutions from BSI. An In Vitro Diagnostic Notified Body. Expertise and experience. IVD regulatory solutions
Flexible, robust solutions from BSI An In Vitro Diagnostic Notified Body Expertise and experience IVD regulatory solutions Updated May 2017 Your guide to the In Vitro Diagnostic Directive The purpose of
More informationASIT BIOTECH ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING AND TO LIST ITS SHARES ON EURONEXT BRUSSELS AND EURONEXT PARIS
This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for securities. This announcement is not a prospectus
More informationMolecular Diagnostics at the Point of Need Interim Results (to Dec-17) 20 March 2018
Molecular Diagnostics at the Point of Need Interim Results (to Dec-17) 20 March 2018 2 Decentralising molecular diagnostics DOCUMENT INFORMATION The information contained in this document and made verbally
More informationSAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014
Mexico Orthopedic Prosthetics Market Outlook to 2020 Reference Code: GDMECC0156DB Publication Date: February 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationINVESTOR PRESENTATION March 2017 A DIVERSIFIED CANNABIS TECHNOLOGY COMPANY
INVESTOR PRESENTATION March 2017 A DIVERSIFIED CANNABIS TECHNOLOGY COMPANY Overview MJ BioPharma is a cannabis technology company led by a team of experienced business and medical professionals and researchers.
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationPREVIEW. Benchmarking European Investigator Payments Industry Standard Research
PREVIEW Benchmarking European Investigator Payments Info@ISRreports.com 2014 Industry Standard Research www.isrreports.com Report Overview This report provides an analysis of Europe s clinical trial compensation
More informationEARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles
EARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles BrainDTech team Dr. Fabio Bianco, PhD Chief Executive Officier PhD in Pharmacology, Degree in Biotech
More informationValuing and Licensing Intellectual Property. Richard Williams
c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations
More informationA LEADING GLOBAL HEALTH CARE GROUP. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY
A LEADING GLOBAL HEALTH CARE GROUP Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More information13 15 SEPTEMBER 2017 SERVING LABORATORY MANAGEMENT & DIOGNOSTIC NETWORKS GLOBALLY BARCELONA CONGRESS CENTRE, BARCELONA, SPAIN
13 15 SEPTEMBER 2017 BARCELONA CONGRESS CENTRE, BARCELONA, SPAIN SERVING LABORATORY MANAGEMENT & DIOGNOSTIC NETWORKS GLOBALLY www.medlabeurope.com medlabeurope@informa.com +34 518890041 INTRODUCTION It
More informationAkers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers
Akers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers 1 All statements pertaining to future financial and/or operating results,
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors General Presentation, Fresenius SE & Co. KGaA, Investor Relations Copyright, August 2016
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationThe Long and Winding Road of Unique Device Identifier (UDI) Implementation: A Small Company Perspective
The Long and Winding Road of Unique Device Identifier (UDI) Implementation: A Small Company Perspective Daniel Simpson, RAC (US,CAN), ASQ CBA Sr. Director of Quality and Regulatory Affairs Corgenix, Inc
More informationMRI Systems Market to 2018
MRI Systems Market to 2018 Technological advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth GBI Research Report Guidance GBI Research Report
More informationCoding Essentials for Laboratories 2017
Coding Essentials for Laboratories 2017 An Easy-to-Use Tool for Coding and Reimbursement Compliance Prepared and Published By: MedLearn Publishing A Division of Panacea Healthcare Solutions, Inc. 287 East
More informationInvestor Presentation
Investor Presentation 2017 www.enzo.com LEGAL DISCLAIMER Except for historical information, the matters discussed herein may be considered "forward looking" statements within the meaning of Section 27A
More informationIDEX ASA. DNB SME Conference, April 2017 IDEX.NO
IDEX ASA DNB SME Conference, April 2017 IDEX.NO DISCLAIMER This presentation includes and is based, inter alia, on forward-looking information and statements that are subject to risks and uncertainties
More informationBrazil Gastric Balloon Procedures Outlook to 2020
Brazil Gastric Balloon Procedures Outlook to 2020 Reference Code: GDMECC0472PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationWhite paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act
White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act Published: July 2014 Author: Anantharaman Kavassery Viswanthan Anantharaman Kavassery Viswanathan
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More information30 th Annual JP Morgan Healthcare Conference January 10, Carl Hull, Chairman and CEO Herm Rosenman, SVP and CFO
An Innovative Growth Company in Molecular Diagnostics 30 th Annual JP Morgan Healthcare Conference January 10, 2012 Carl Hull, Chairman and CEO Herm Rosenman, SVP and CFO Safe Harbor Statement Any statements
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationAnnual General Meeting Roche Holding Ltd 6 March 2012
r Annual General Meeting Roche Holding Ltd 6 March 2012 Address by Franz B. Humer Chairman of the Board of Directors (Check against delivery.) Address by Franz B. Humer Page 2/12 Dear Shareholders, Ladies
More informationInvestor Presentation
Tony Toohey CEO & Managing Director Investor Presentation August, 2013 1 Disclaimer This document and any oral presentation accompanying it has been prepared in good faith. However, no express or implied
More informationDIAGNOSTICS: COLLECTION TO DETECTION. Results that matter.
DIAGNOSTICS: COLLECTION TO DETECTION Results that matter. LEADING THE WAY IN DIAGNOSTIC SOLUTIONS Diagnostics is the dynamic, growing industry that relies on faster and more accurate results to improve
More information11% of employees are dedicated to R&D. 11 billions IVD market size 3,000 companies 75,000 people employed. 40,000 IVD products
About edma EDMA The European Diagnostic Manufacturers Association is an international, non-profit organisation representing the interests of the European in vitro diagnostics industry at the European and
More informationIdorsia Company Profile
Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has
More informationCreating New Business. In a Large Company. Dr. Lee Ng. Business Director. New Business Creation
In a Large Company Business Director New Business Creation Agilent Technologies, Inc. 5301 Steven s Creek Blvd, Santa Clara, CA 95051 lee_ng@agilent.com lee_ng@alum.mit.edu Page 1 Outline Agilent Creating
More informationBIOANALYTICAL AND BIOMEDICAL MICROSENSORS. Gerald A. URBAN Laboratory for Sensors IMTEK Freiburg/Germany. G. A. Urban Slide 1 3
BIOANALYTICAL AND BIOMEDICAL MICROSENSORS Gerald A. URBAN Laboratory for Sensors IMTEK Freiburg/Germany G. A. Urban Slide 1 3 DISTINGUISHING FEATURES Unique combination of Computer Science and Microsystems
More informationExamples of founding and evolving leading LifeScience companies. November 2016
Examples of founding and evolving leading LifeScience companies November 2016 Peter Pohl Born: in Salzburg Love: my wife and my two children (age 9&7) Education: Business Adminstration Serial entrepreneur
More informationFuture of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities
Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities Introduction The report analyzes current and potential world molecular diagnostics markets and advances in the field.
More informationBIOCRATES Life Sciences AG Short Company Presentation
BIOCRATES Life Sciences AG Short Company Presentation Dr. Alexandra C. Gruber MBA MMFin Director Business Development / Marketing Austria Showcase Life Science Japan, Tokyo, December 2010 BIOCRATES Life
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationMolecular Diagnostics
Molecular Diagnostics Positioning the Laboratory for the Future Through Scalable Lab Developed Test Workflows, Clinical-level Quality, & Operational Efficiency Path to the heart of healthcare Change It
More informationM3, Inc. Presentation Material. July Copyright 2017 M3, Inc. All rights reserved.
M3, Inc. Presentation Material July 2017 Copyright 2017 M3, Inc. All rights reserved. The following presentation contains forecasts, future plans, management targets and other forward-looking projections
More informationMr. Lou Panaccio Executive Chairman
Mr. Lou Panaccio Executive Chairman 1 Overview Objective Develop compelling multiplexed test solutions for the $4BN global molecular diagnostic testing industry using our silica bead based AmpaSand technology
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationSirtex Medical Limited
Sirtex Medical Limited Market Update 2011 Half Year Results Gilman Wong CEO Darren Smith CFO 9-10 March 2011 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Understanding the Sirtex
More informationLeveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationPT Prodia Widyahusada Tbk. 9M2017 Results Update 26 October 2017
PT Prodia Widyahusada Tbk 9M2017 Results Update 26 October 2017 Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation
More informationStrengthening the experience and embracing the shift
Strengthening the experience and embracing the shift THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES. IT IS SOLELY FOR USE AT A CAPITAL MARKETS EVENT AND IS PROVIDED
More informationECPI GLOBAL RENEWABLE ENERGY EQUITY INDEX
ECPI FACTSHEET ECPI GLOBAL EQUITY INDEX The index selects the 40 highest ESG-rated Companies active in the production or trading of energy from sources which are inexhaustible REV. NOVEMBER 14 INFORMATION
More information